NovoCure Ltd (NVCR) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 30 days, typically, give or take 14 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Oct 29, 2026before open 29 8-K
Q2 FY2026Thu, Jul 23, 2026before open 23 8-K
Q1 FY2026Thu, Apr 30, 2026before open 30 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Thu, Oct 30, 2025before open 30 8-K
Q2 FY2025Thu, Jul 24, 2025before open 24 8-K
Q1 FY2025Thu, Apr 24, 2025before open 24 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Document Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide Strong performance drove increased net revenue guidance for full-year 2026 to $736 million - $743 million and adjusted EBITDA guidance to $24 million - $34 million Optune Pax® approved by Japan's Ministry of Health, Labour and Welfare for the treatment of locally advanced pancreatic cancer BAAR, Switzerland – October 29, 2026 - Novocure (Nasdaq: NVCR) today reported financial resul" exhibit
Q3 FY2026 "Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”" exhibit
Q3 FY2026 "Guidance: Novocure’s updated guidance for the full year 2026, as of October 29, 2026, is summarized below:" exhibit
Q3 FY2026 "Adjusted EBITDA*: $24 million - $34 million (previous: $0 million - $15 million) This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $30 million and $34 million, foreign exchange rates as of September 30, 2026, and quarterly gross margin in the mid-to-high 70s percent." exhibit
Q2 FY2026 "Optune Pax received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. 2026 financial guidance: Novocure’s updated guidance for the full year 2026, as of July 23, 2026, is summarized below:" exhibit
Q2 FY2026 "Adjusted EBITDA*: $0 million - $15 million (previous: $(15) million - $0 million) This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, foreign exchange rates as of June 30, 2026 and consistent quarterly gross margin in the mid-70s percent." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NVCR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NVCR

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

NVCR earnings date badge

HTML

<a href="https://veritasdata.dev/company/NVCR/"><img src="https://veritasdata.dev/embed/NVCR.svg" alt="NVCR earnings date" width="240" height="56"></a>

Markdown

[![NVCR earnings date](https://veritasdata.dev/embed/NVCR.svg)](https://veritasdata.dev/company/NVCR/)

Script

<script async src="https://veritasdata.dev/embed/NVCR.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NVCR"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.